295 related articles for article (PubMed ID: 29205362)
1. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.
Winder DM; Chattopadhyay A; Muralidhar B; Bauer J; English WR; Zhang X; Karagavriilidou K; Roberts I; Pett MR; Murphy G; Coleman N
J Pathol; 2011 Nov; 225(3):448-62. PubMed ID: 21952923
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.
Kucia-Tran JA; Tulkki V; Smith S; Scarpini CG; Hughes K; Araujo AM; Yan KY; Botthof J; Pérez-Gómez E; Quintanilla M; Cuschieri K; Caffarel MM; Coleman N
Br J Cancer; 2016 Jul; 115(2):212-22. PubMed ID: 27351213
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.
Caffarel MM; Coleman N
J Pathol; 2014 Mar; 232(4):386-90. PubMed ID: 24659184
[TBL] [Abstract][Full Text] [Related]
7. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
8. Virus and Host Events in Squamous Carcinogenesis.
Coleman N
Keio J Med; 2016; 65(4):78. PubMed ID: 28025425
[TBL] [Abstract][Full Text] [Related]
9. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
10. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome.
Ng G; Winder D; Muralidhar B; Gooding E; Roberts I; Pett M; Mukherjee G; Huang J; Coleman N
J Pathol; 2007 Jul; 212(3):325-34. PubMed ID: 17516585
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Caffarel MM; Chattopadhyay A; Araujo AM; Bauer J; Scarpini CG; Coleman N
J Pathol; 2013 Oct; 231(2):168-79. PubMed ID: 23765377
[TBL] [Abstract][Full Text] [Related]
12. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice.
Adrian-Segarra JM; Sreenivasan K; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 Dec; 293(52):20181-20199. PubMed ID: 30373773
[TBL] [Abstract][Full Text] [Related]
13. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.
Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM
J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R
Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages.
Zhang X; Li J; Qin JJ; Cheng WL; Zhu X; Gong FH; She Z; Huang Z; Xia H; Li H
J Lipid Res; 2017 May; 58(5):895-906. PubMed ID: 28258089
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
18. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M pathway plays a major role in the renal acute phase response.
Luyckx VA; Cairo LV; Compston CA; Phan WL; Mueller TF
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F875-83. PubMed ID: 19158344
[TBL] [Abstract][Full Text] [Related]
20. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]